The Ebola pathogen outbreak in Western Africa controlled much of the reports in 2014. The highly communicable pathogen spreads quickly and kills over half of those who become infected, leading to major panics across multiple continents. While the vast majority of the dead are in Africa, health employees did bring the pathogen home to other states and continents.
For all of the problems and focus upon doomsday scenarios on what the pathogen could do, there are actually dome economic benefits of Ebola virus break outs. The business benefits principally breakdown between non-profit or state groups and for-profit biotechnology corporations.
Executive or help setups like the Red Cross or the CDC have a tendency to see increases in funding in events like these. The business benefits to them are direct and help out those on the ground suffering or aiding and containing an outbreak.
This containment keeps economic disruption when funding is adequate to turn the tide of an onset.
The longer term commercial benefits of Ebola virus onsets are biotech corporations working on vaccines or drugs that might improve survival rates of those infected with Ebola. One such firm is Tekmira, that has been given blessings by the FDA to expand testing on in its experimental Ebola drug for larger scale clinical trials.
Sarepta Therapeutics, Nanoviricides and BioCryst Pharmaceuticals are other biotech outfits that would see increased business in the future if their own Ebola drugs and medications prove to be of price.
While the 2014 Ebola break out is first to have caught world attention as much as it probably did, it was hardly the first outbreak. Others have happened, and more will occur in days to come. Any business which has an Ebola drug or vaccine on the market that proves effective can be certain to see a rise in business in times to come.
For all of the problems and focus upon doomsday scenarios on what the pathogen could do, there are actually dome economic benefits of Ebola virus break outs. The business benefits principally breakdown between non-profit or state groups and for-profit biotechnology corporations.
Executive or help setups like the Red Cross or the CDC have a tendency to see increases in funding in events like these. The business benefits to them are direct and help out those on the ground suffering or aiding and containing an outbreak.
This containment keeps economic disruption when funding is adequate to turn the tide of an onset.
The longer term commercial benefits of Ebola virus onsets are biotech corporations working on vaccines or drugs that might improve survival rates of those infected with Ebola. One such firm is Tekmira, that has been given blessings by the FDA to expand testing on in its experimental Ebola drug for larger scale clinical trials.
Sarepta Therapeutics, Nanoviricides and BioCryst Pharmaceuticals are other biotech outfits that would see increased business in the future if their own Ebola drugs and medications prove to be of price.
While the 2014 Ebola break out is first to have caught world attention as much as it probably did, it was hardly the first outbreak. Others have happened, and more will occur in days to come. Any business which has an Ebola drug or vaccine on the market that proves effective can be certain to see a rise in business in times to come.
About the Author:
my name is alfred obi I've been a biological scientist for years teaching individuals on ebola virus disease update and ebola virus disease which has influenced most states in africa be at liberty to visit my website for your free protecting gear on ebola thanks.
No comments:
Post a Comment